对分子瘤委员会关于临床有效性和评估差距的数据进行系统审查和元分析
Beryl Primrose Gladstone1,2, Janina Beha3, Arisa Hakariya4
1Department of Internal Medicine I, Eberhard-Karls University Tübingen, Tübingen, Germany. primrose.beryl@med.uni-tuebingen.de.
NPJ precision oncology
|April 2, 2025
概括
分子瘤委员会 (MTBs) 通过推向目标治疗来改善癌症护理. 本综述表明,MTB引导的治疗可以提高患者的生存率,并减少固体瘤的疾病进展.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 个性化医疗是个性化的医疗.
背景情况:
- 分子瘤板 (MTBs) 对精确瘤学至关重要.
- 将基因组数据整合到临床决策中是复杂的.
研究的目的:
- 系统地审查和元分析MTB建议对患者结果的影响.
- 在各种固体瘤中评估MTB导向疗法的疗效.
主要方法:
- 对34项涉及12,176名患者的研究 (2020-2024) 的系统综述和元分析.
- 分析整体生存 (OS),无进展生存 (PFS) 和客观反应率 (ORR).
主要成果:
- 20.8%的患者接受了MTB推的疗法.
- 接受MTB治疗的患者表现出改善的OS (HR 0.46) 和PFS (HR 0.65).
- 平均生存期: 13.5个月,平均PFS: 4.5个月,ORR: 5-57%.
结论:
- MTB评估显著有利于患有固体瘤的患者.
- 需要标准化的标准来进行一致的MTB评估和结果比较.
相关概念视频
Cancer Survival Analysis
311
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
311
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


